<DOC>
	<DOCNO>NCT01858428</DOCNO>
	<brief_summary>This study design evaluate safety efficacy Paclitaxel-coated percutaneous transluminal angioplasty ( PTA ) Catheter treatment patient peripheral arterial disease .</brief_summary>
	<brief_title>Pivotal Trial Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon</brief_title>
	<detailed_description>The ILLUMENATE Pivotal study prospective , randomize , multi-center , single-blind study include 360 subject approximately forty-five ( 45 ) site across United States evaluate CVI Paclitaxel-coated PTA Catheter compare bare percutaneous transluminal angioplasty balloon catheter ( bare balloon catheter ) treatment de-novo post-PTA occluded/stenotic reoccluded/restenotic ( except in-stent ) SFA and/or popliteal artery .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Subjects symptomatic leg ischemia , require treatment Superficial Femoral Artery ( SFA ) popliteal artery . Known intolerance study medication , paclitaxel contrast agent opinion investigator adequately pretreated</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>